New labs being built in Philadelphia due to gene, cell therapy demand

By The Science Advisory Board staff writers

July 1, 2020 -- Real estate developer MRA Group is building lab spaces in Philadelphia to meet the region's growing demand for cell and gene therapy.

Prospective life science companies have been attracted to the area since Philadelphia was recognized as a "Big4Bio" region but have been disappointed by the lack of available lab space, according to MRA.

The group has already added AnPac Bio, an international biotechnology company, to the space. Exegenesis Bio, a gene therapy company including its Jefferson Institute for Bioprocessing, will be moving in later this summer.

The developer hopes to complete two specialized multitenant life science lab buildings, totaling about 140,000 sq ft, in Philadelphia and one of its nearby suburbs by the end of the year. Space can be leased now.

Avantor expands its innovation center for bioprocessing
Avantor is increasing its investment in bioprocessing infrastructure by expanding its innovation center in Bridgewater, NJ.
Genprex expands gene therapy manufacturing
Genprex has expanded its program to manufacture tumor suppressor candidate 2 (TUSC2) with a new manufacturing agreement with partner Aldevron.
Sexton, BioSpherix collaborate to support cell & gene therapy needs
Sexton Biotechnologies is partnering with BioSpherix Medical on the final steps of downstream bioprocessing, fill-finish.
CSL Behring, Seattle Children's to develop gene therapies
CSL Behring, a biotechnology company, and Seattle Children's Research Institute announced that the organizations have entered a strategic alliance to...
LabShares Newton offers free space for COVID-19 research
LabShares Newton is offering free, fully equipped biosafety level 2 lab space, facilities, and resources for researchers addressing the global COVID-19...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter